☆ 4.7 Editorial Material

New Era in Radiation Oncology for Lung Cancer: Recognizing the Importance of Cardiac Irradiation

JOURNAL OF CLINICAL ONCOLOGY (2017)

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 35, Issue 13, Pages 1381-+

Publisher

AMER SOC CLINICAL ONCOLOGY

DOI: 10.1200/JCO.2016.71.5581

Keywords

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Definitive intensity modulated proton re-irradiation for lung cancer in the immunotherapy era

James R. Janopaul-Naylor, Yichun Cao, Neal S. McCall, Jeffrey M. Switchenko, Sibo Tian, Haijian Chen, William A. Stokes, Aparna H. Kesarwala, Mark W. McDonald, Joseph W. Shelton, Jeffrey D. Bradley, Kristin A. Higgins

Summary: Definitive IMPT re-irradiation for lung cancer can prolong disease control with limited toxicity, particularly in the immunotherapy era.

FRONTIERS IN ONCOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Treatment patterns and survival outcomes for patients with non-small cell lung cancer in the UK in the preimmunology era: a REAL-Oncology database analysis from the I-O Optimise initiative

Michael Snee, Sue Cheeseman, Matthew Thompson, Majid Riaz, Will Sopwith, Laure Lacoin, Carlos Chaib, Melinda J. Daumont, John R. Penrod, Geoff Hall

Summary: A retrospective cohort study was conducted at Leeds Teaching Hospital NHS Trust to report characteristics, treatment, and overall survival trends of NSCLC patients from 2007 to 2018. The study found that survival rates for patients diagnosed at stage I and IIIA improved over time, possibly due to increased utilization of stereotactic ablative radiation, surgery, and chemoradiation. Conversely, survival outcomes remained poor for patients diagnosed at stage IIIB-IV, despite the increasing use of systemic anticancer therapy (SACT) for NSQ, and a significant proportion of advanced-stage patients remained untreated.

BMJ OPEN (2021)

Add to Collection

Review Oncology

Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy

Anne Sophie V. M. van den Heerik, Nanda Horeweg, Stephanie M. de Boer, Tjalling Bosse, Carien L. Creutzberg

Summary: Endometrial cancer is primarily treated with surgery, with adjuvant treatments such as radiotherapy and chemotherapy being considered based on clinico-pathological risk factors. Recent studies have shown the effectiveness of different treatment strategies for different risk levels of endometrial cancer, highlighting the importance of personalized treatment approaches. Molecular classification and targeted treatments are emerging as potential advancements in the field, with ongoing trials exploring their impact on patient outcomes.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2021)

Add to Collection

Review Immunology

Radiotherapy for extensive-stage small-cell lung cancer in the immunotherapy era

Huanhuan Li, Yangzhi Zhao, Tiangang Ma, Hao Shao, Tiejun Wang, Shunzi Jin, Zhongshan Liu

Summary: Chemotherapy and immunotherapy are the main treatments for ES-SCLC, but the complete response rate is low. Previous studies have shown that cTRT can improve overall survival in ES-SCLC patients who respond well to chemotherapy, but its efficacy and safety in the era of immunotherapy are unclear due to a lack of prospective studies.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Article Oncology

Radiation therapy for extensive-stage small-cell lung cancer in the era of immunotherapy

Yaru Tian, Ji Ma, Xuquan Jing, Xiaoyang Zhai, Yuying Li, Zhijun Guo, Jinming Yu, Hui Zhu

Summary: Unlike NSCLC, the progression of SCLC is slow. ES-SCLC poses a serious threat to human health with a low 5-year survival rate. Chemotherapy has been the first-line treatment, but anti-PD-L1 checkpoint blockades have emerged as standard therapy. The combination of radiation therapy and immunotherapy in ES-SCLC has limited evidence and requires further prospective trials.

CANCER LETTERS (2022)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Bridging the Communication Gaps: A Prospective Single-Arm Pilot Study Testing the Feasibility of Interdisciplinary Radiotherapy Planning in Locally Advanced Lung Cancer

Michael K. Farris, Niema B. Razavian, Ryan T. Hughes, James D. Ververs, Anna C. Snavely, Charles M. Leyrer, Karen E. Tye, Laura F. Allen, Heather Pacholke, Kathryn E. Weaver, Paul M. Bunch, Michael D. Chan, Hollins Clark, Gregory Puthoff, Joshua C. Farris, Cole R. Steber, Stacy Wentworth, Beverly J. Levine, Chandylen L. Nightingale, Janardhana Ponnatapura

Summary: Multidisciplinary collaboration between radiologists and radiation oncologists can optimize radiotherapy planning for locally advanced lung cancer and improve treatment outcomes.

ACADEMIC RADIOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Role of Cardiac Biomarkers in Non-Small Cell Lung Cancer Patients

Valerio Nardone, Alfonso Reginelli, Giuseppina De Marco, Giovanni Natale, Vittorio Patane, Marco De Chiara, Mauro Buono, Gaetano Maria Russo, Riccardo Monti, Giovanni Balestrucci, Maria Salvarezza, Gaetano Di Guida, Emma D'Ippolito, Angelo Sangiovanni, Roberta Grassi, Ida D'Onofrio, Maria Paola Belfiore, Giovanni Cimmino, Carminia Maria Della Corte, Giovanni Vicidomini, Alfonso Fiorelli, Antonio Gambardella, Floriana Morgillo, Salvatore Cappabianca

Summary: Treatment-induced cardiac toxicity is a significant issue in NSCLC patients, with no available biomarkers in clinical practice. The Agatston score (or CAD score) is a novel and easy-to-calculate marker for quantitative analysis of calcium plaque in the coronary on CT. Our study aimed to correlate cardiac biomarkers with overall survival in NSCLC patients.

DIAGNOSTICS (2023)

Add to Collection

Article Oncology

Associations between cardiac irradiation and survival in patients with non-small cell lung cancer: Validation and new discoveries in an independent dataset

Sindu Vivekanandan, John D. Fenwick, Nicholas Counsell, Niki Panakis, Robert Stuart, Geoff S. Higgins, Maria A. Hawkins

Summary: This study found that in patients with locally-advanced non-small-cell lung cancer, overall survival was more strongly associated with doses to the left atrial wall and aortic valve region. The best multivariable model included these doses as well as the mean aortic valve dose.

RADIOTHERAPY AND ONCOLOGY (2021)

Add to Collection

Review Oncology

Multidisciplinary Management of Brain Metastases from Non-Small Cell Lung Cancer in the Era of Immunotherapy

Lisa Sudmeier, Sibo Tian, Kristin A. Higgins

Summary: Brain metastases from non-small cell lung cancer often present with neurologic symptoms and should be treated promptly with dexamethasone and evaluated by a neurosurgeon for possible surgical intervention. Surgery is recommended to alleviate symptoms and prevent irreversible neurologic damage, followed by stereotactic radiosurgery within 2-4 weeks. Treatment choice should be guided by molecular testing, starting systemic therapy as soon as possible in patients not suitable for surgery. Best supportive care may be considered in patients with poor performance status. Treatment decisions should consider patient goals and involve a multidisciplinary approach.

CURRENT TREATMENT OPTIONS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

Beyond Abscopal Effect: A Meta-Analysis of Immune Checkpoint Inhibitors and Radiotherapy in Advanced Non-Small Cell Lung Cancer

Francesco Fiorica, Umberto Tebano, Milena Gabbani, Mariasole Perrone, Sonia Missiroli, Massimiliano Berretta, Jacopo Giuliani, Andrea Bonetti, Andrea Remo, Eva Pigozzi, Andrea Tontini, Giuseppe Napoli, Nicoletta Luca, Daniela Grigolato, Paolo Pinton, Carlotta Giorgi

Summary: The combination of immune checkpoint inhibitors (ICI) plus radiotherapy (RT) in advanced or metastatic non-small cell lung cancer (NSCLC) patients significantly increases 1- and 3-year overall survival and progression-free survival, compared to ICI or RT alone, according to the study findings.

CANCERS (2021)

Add to Collection

Article Medicine, General & Internal

Pirfenidone for the prevention of radiation-induced lung injury in patients with locally advanced oesophageal squamous cell carcinoma: a protocol for a randomised controlled trial

Cheng Chen, Bangwei Zeng, Dan Xue, Rongxiang Cao, Siqin Liao, Yong Yang, Zhihua Li, Mingqiang Kang, Chun Chen, Benhua Xu

Summary: This study aims to evaluate the efficacy and safety of pirfenidone in preventing radiation-induced lung injury (RILI) in patients with oesophageal squamous cell carcinoma (ESCC) during thoracic radiation therapy. The study design is a randomized, placebo-controlled phase 2 trial, with the primary endpoint being the incidence of lung injury.

BMJ OPEN (2022)

Add to Collection

Article Oncology

Utility of Prophylactic Cranial Irradiation for Extensive-Stage Small-Cell Lung Cancer in the MRI Screening Era

Andrew Keller, Siddharth Ghanta, Joshua L. Rodriguez-Lopez, Ankur Patel, Sushil Beriwal

Summary: This study highlights the importance of screening with MRI following chemotherapy, as nearly 16% of patients with response to chemotherapy were diagnosed with unsuspected brain metastases near completion of treatment. PCI is associated with a reduction in brain metastases, but does not have a demonstrable impact on overall survival in the era of MRI screening.

CLINICAL LUNG CANCER (2021)

Add to Collection

Review Oncology

Antibody-drug conjugates in lung cancer: dawn of a new era?

Niamh Coleman, Timothy A. A. Yap, John V. V. Heymach, Funda Meric-Bernstam, Xiuning Le

Summary: Antibody-drug conjugates (ADCs) are a growing class of oncology drugs that combine cytotoxic chemotherapy with targeted therapy to deliver potent agents to cancer cells. In lung cancer treatment, ADCs have emerged as potential options, with FDA-approved and breakthrough therapy designated ADCs available. Early-phase trials are also exploring novel ADCs for advanced lung cancer. This review discusses the structure, mechanism of action, recent progress, toxicity profiles, and strategies to enhance potency and overcome resistance of ADCs in lung cancer, as well as novel ADC strategies using non-cytotoxic payloads.

NPJ PRECISION ONCOLOGY (2023)

Add to Collection

Review Oncology

Current State of Personalized Genitourinary Cancer Radiotherapy in the Era of Precision Medicine

Sophia C. Kamran, Jason A. Efstathiou

Summary: Radiation therapy is crucial in the management of genitourinary malignancies, with technological advancements improving outcomes and reducing toxicities. Recent advances in imaging and genomic techniques can provide personalized tumor and patient information for treatment decisions. Targeted molecular therapies based on tumor biology offer individualized treatment recommendations.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

MArkerless image Guidance using Intrafraction Kilovoltage x-ray imaging (MAGIK): study protocol for a phase I interventional study for lung cancer radiotherapy

Marco Mueller, Jeremy Booth, Adam Briggs, Dasantha Jayamanne, Vanessa Panettieri, Sashendra Senthi, Chun-Chien Shieh, Paul Keall

Summary: This study introduces a markerless tumor tracking technique for accurate and optimal radiotherapy. The feasibility of this technique will be investigated through an interventional trial, and the accuracy will be evaluated using implanted fiducial markers.

BMJ OPEN (2022)

Add to Collection

Article Oncology

Insurance Status is an Independent Predictor of Overall Survival in Patients With Stage III Non-small-cell Lung Cancer Treated With Curative Intent

Stephanie R. Rice, Melissa A. L. Vyfhuis, Katherine A. Scilla, Whitney M. Burrows, Neha Bhooshan, Mohan Suntharalingam, Martin J. Edelman, Josephine Feliciano, Shahed N. Badiyan, Charles B. Simone, Soren M. Bentzen, Steven J. Feigenberg, Pranshu Mohindra

CLINICAL LUNG CANCER (2020)

Add to Collection

Article Oncology

Hypofractionated vs. conventional radiation therapy for stage III non-small cell lung cancer treated without chemotherapy

Michelle Iocolano, Aaron T. Wild, Margaret Hannum, Zhigang Zhang, Charles B. Simone, Daphna Gelblum, Abraham J. Wu, Andreas Rimner, Annemarie F. Shepherd

ACTA ONCOLOGICA (2020)

Add to Collection

Review Health Care Sciences & Services

Proton Therapy for Partial Breast Irradiation: Rationale and Considerations

J. Isabelle Choi, Jana Fox, Richard Bakst, Shaakir Hasan, Robert H. Press, Arpit M. Chhabra, Brian Yeh, Charles B. Simone, Oren Cahlon

Summary: Partial breast irradiation (PBI) delivered with proton therapy offers a shorter treatment duration and reduced toxicities, targeting less non-target breast tissue and limiting unnecessary radiation dose to thoracic organs. Proton therapy is a precision radiotherapy technology that further limits normal tissue exposure to improve quality of life for early stage breast cancer patients.

JOURNAL OF PERSONALIZED MEDICINE (2021)

Add to Collection

Article Oncology

Quantitative Assessment of 3D Dose Rate for Proton Pencil Beam Scanning FLASH Radiotherapy and Its Application for Lung Hypofractionation Treatment Planning

Minglei Kang, Shouyi Wei, J. Isabelle Choi, Charles B. Simone, Haibo Lin

Summary: This study focuses on quantifying the dose rate of organs-at-risk and targets based on three proposed proton PBS dose rate metrics, showing significant impact of differences in dose rate metrics on the assessment of organ-at-risk dose rate, posing challenges to the clinical implementation of FLASH. Additional investigations are needed to explore the correlation between FLASH efficacy and the dose rate metrics in proton PBS therapy.

CANCERS (2021)

Add to Collection

Article Oncology

A Novel Proton Pencil Beam Scanning FLASH RT Delivery Method Enables Optimal OAR Sparing and Ultra-High Dose Rate Delivery: A Comprehensive Dosimetry Study for Lung Tumors

Shouyi Wei, Haibo Lin, J. Isabelle Choi, Charles B. Simone, Minglei Kang

Summary: This study compares the performance of single-energy Bragg peak proton beams with transmission proton beams in lung tumor treatment planning, finding that Bragg peak plans achieve superior dosimetry performances in OARs while maintaining comparable dose rate performances. Beam angle optimization further improves OAR dosimetry parameters without compromising the 3D FLASH dose rate coverage.

CANCERS (2021)

Add to Collection

Review Oncology

Proton Therapy in the Management of Pancreatic Cancer

Jana M. Kobeissi, Charles B. Simone, Haibo Lin, Lara Hilal, Carla Hajj

Summary: Radiation therapy plays a central role in the management of pancreatic cancer, and proton therapy is an emerging treatment modality. Proton irradiation remains a challenge in radiation therapy, but no significant differences in oncologic outcomes and toxicity rates have been shown compared to photon radiation treatment.

CANCERS (2022)

Add to Collection

Review Oncology

Proton Therapy in the Management of Luminal Gastrointestinal Cancers: Esophagus, Stomach, and Anorectum

Jana M. Kobeissi, Charles B. Simone, Lara Hilal, Abraham J. Wu, Haibo Lin, Christopher H. Crane, Carla Hajj

Summary: Radiation treatment is crucial in managing luminal gastrointestinal cancers, particularly esophageal and anorectal cancers. Proton therapy is gaining interest for its ability to decrease dose to nearby organs at risk. In esophageal cancer, protons have shown superior dosimetric characteristics in sparing organs at risk, but clinical significance is conflicting. However, evidence suggests that protons offer similar or improved oncologic outcomes with reduced toxicity compared to photons. In anorectal cancers, proton therapy has shown improved organ sparing, but clinical data is limited and toxicity benefits have not been clinically proven.

CANCERS (2022)

Add to Collection

Review Oncology

Proton Therapy in the Management of Hepatocellular Carcinoma

Jana M. Kobeissi, Lara Hilal, Charles B. Simone, Haibo Lin, Christopher H. Crane, Carla Hajj

Summary: This review provides a concise and comprehensive summary on the use of proton therapy in the management of hepatocellular carcinoma (HCC). Proton radiation therapy plays a central role in the treatment of HCC, and evidence suggests it may be superior to photons in terms of survival and toxicity outcomes.

CANCERS (2022)

Add to Collection

Article Oncology

An International Consensus on the Design of Prospective Clinical-Translational Trials in Spatially Fractionated Radiation Therapy for Advanced Gynecologic Cancer

Beatriz E. Amendola, Anand Mahadevan, Jesus Manuel Blanco Suarez, Robert J. Griffin, Xiaodong Wu, Naipy C. Perez, Daniel S. Hippe, Charles B. Simone Ii, Majid Mohiuddin, Mohammed Mohiuddin, James W. Snider, Hualin Zhang, Quynh-Thu Le, Nina A. Mayr

Summary: SFRT shows promising potential as a new treatment modality for challenging tumors. However, the development of clinical trials is hindered by the variability in SFRT methods and the unfamiliarity with heterogeneous dosing, requiring a broad consensus.

CANCERS (2022)

Add to Collection

Article Medicine, General & Internal

Application of Spectral Algorithm Applied to Spatially Registered Bi-Parametric MRI to Predict Prostate Tumor Aggressiveness: A Pilot Study

Rulon Mayer, Baris Turkbey, Peter L. Choyke, Charles B. Simone

Summary: This study predicts the risk of clinically significant prostate cancer (CsPCa) and correlates it with the ISUP grade using processed SCR derived from SRBP-MRI. The results show a high correlation between SCR values and ISUP grade and CsPCa/CiPCa, indicating the potential of SRBP-MRI in non-invasive management of prostate cancer.

DIAGNOSTICS (2023)

Add to Collection

Article Oncology

Proton Bragg Peak FLASH Enables Organ Sparing and Ultra-High Dose-Rate Delivery: Proof of Principle in Recurrent Head and Neck Cancer

Michael Pennock, Shouyi Wei, Chingyun Cheng, Haibo Lin, Shaakir Hasan, Arpit M. Chhabra, J. Isabelle Choi, Richard L. Bakst, Rafi Kabarriti, Charles B. Simone II, Nancy Y. Y. Lee, Minglei Kang, Robert H. Press

Summary: Bragg peak proton FLASH is a novel radiotherapy technique that combines ultra-high dose rates and conformal organ sparing for cancer treatment. By modifying the planning software and treatment delivery, Bragg peak FLASH can improve organ sparing and target coverage compared to conventional proton therapy. This study demonstrates the potential benefits of Bragg peak proton FLASH in head and neck reirradiation.

CANCERS (2023)

Add to Collection

Article Oncology

Pencil Beam Scanning Bragg Peak FLASH Technique for Ultra-High Dose Rate Intensity-Modulated Proton Therapy in Early-Stage Breast Cancer Treatment

Grant Lattery, Tyler Kaulfers, Chingyun Cheng, Xingyi Zhao, Balaji Selvaraj, Haibo Lin, Charles B. Simone II, J. Isabelle Choi, Jenghwa Chang, Minglei Kang

Summary: This study focused on developing ultra-high dose rate intensity-modulated proton therapy (IMPT) for hypofractionated treatment of early-stage breast cancer. The results showed that the Bragg peak FLASH-RT technique achieved comparable plan quality to conventional IMPT, demonstrating the feasibility of early-stage breast cancer clinical applications.

CANCERS (2023)

Add to Collection

Article Oncology

The Applications and Pitfalls of Cone-Beam Computed Tomography-Based Synthetic Computed Tomography for Adaptive Evaluation in Pencil-Beam Scanning Proton Therapy

Pingfang Tsai, Yu-Lun Tseng, Brian Shen, Christopher Ackerman, Huifang A. Zhai, Francis Yu, Charles B. Simone II, J. Isabelle Choi, Nancy Y. Lee, Rafi Kabarriti, Stanislav Lazarev, Casey L. Johnson, Jiayi Liu, Chin-Cheng Chen, Haibo Lin

Summary: This study evaluates the potential of cone-beam computed tomography (CBCT)-based synthetic CT (sCT) as an alternative to verification CT (vCT) in proton therapy for enhanced treatment monitoring and early adaptation. The study found that sCT agreed with vCT in regions of homogeneous tissues, but discrepancies were observed in the thorax and abdomen. The study also observed outliers in sCT plans when there was an anatomy change or in low-density regions. The target coverage variance in most sCT cases compared to vCT was less than 5%. The study concludes that the use of sCT allows for precise treatment and prompt early adaptation in proton therapy, but quality assurance of sCT is crucial in the early stages of clinical implementation.

CANCERS (2023)

Add to Collection

Article Medicine, General & Internal

Relationship between Eccentricity and Volume Determined by Spectral Algorithms Applied to Spatially Registered Bi-Parametric MRI and Prostate Tumor Aggressiveness: A Pilot Study

Rulon Mayer, Baris Turkbey, Peter L. Choyke, Charles B. Simone

Summary: This study aims to assess tumor aggressiveness through analysis of bi-parametric MRI images using methods like signal to clutter ratio. The results show that the processed tumor eccentricity and volume computations from spatially registered BP-MRIs have a significant correlation with the ISUP grade.

DIAGNOSTICS (2023)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

The Role of Positron Emission Tomography Imaging in Radiotherapy Target Delineation

Hari Menon, Chunxiao Guo, Vivek Verma, Charles B. Simone

PET CLINICS (2020)

Add to Collection

No Data Available

New Era in Radiation Oncology for Lung Cancer: Recognizing the Importance of Cardiac Irradiation

Journal

Publisher

AMER SOC CLINICAL ONCOLOGY

Keywords

Categories

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Export Citation

Share Paper